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Background/aim: Glial cell-line-derived neurotrophic factor (GDNF) is a well-known regulatory neurotrophic factor on dopaminergic
neurons. Several pathologies have been documented so far in case of any impairment in the dopaminergic system. This study aimed
to investigate the potential protective role of lentiviral GNDF delivery on the small population of tyrosine hydroxylase (TH) positive
dopamine producing striatal neurons after ischemic stroke.
Materials and methods: Fourteen C57BL/6J male mice (8–10 weeks) were intracerebrally treated with lentiviral GDNF (Lv-GDNF) or
vehicle. Ten days after injections, cerebral ischemia was induced by blockage of the middle cerebral artery. Animals were terminated
72 h after ischemia, and their brains were taken for histological and molecular investigations. Following confirmation of GDNF
overexpression, TH immunostaining and immunoblotting were used to evaluate the role of GDNF on dopaminergic neurons. Next,
Fluro Jade C staining was implemented to examine the degree of neuronal degeneration at the damaged parenchyma.
Results: Neither the amount of TH positive dopaminergic neurons nor the expression of TH changed in the Lv-GDNF treated animals
comparing to the vehicle group. On the other hand, GDNF exposure caused a significant increase in the expression of Nurr1, an essential
transcription factor for dopaminergic neurons and Gap43, growth and plasticity promoting protein, in the ischemic striatum. Treatment
with Lv-GDNF gave rise to a significant reduction in the number of degenerated neurons. Finally, enhanced GDNF expression also
induced expression of an important stress-related transcription factor NF-κB as well as the nitric oxide synthase enzymes iNOS and
nNOS in the contralesional hemisphere.
Conclusion: Considering these results together, GDNF’s impact on the survival of striatal dopaminergic neurons is not outstanding for
its neuroprotective role. However, it seems that GDNF conducts several signaling pathways by acting on key transcription factors and
shows its protective feature by fine-tuning the degeneration-related processes.
Key words: Dopaminergic neurons, GDNF, gene therapy, ischemia, lentivirus

1. Introduction
Stroke is a leading cause of death and long-term disabilities
worldwide. Current treatment approaches for stroke are
restricted to fibrinolytic therapies within a narrow time
window after the ischemic attack. Despite the development
of novel clinical strategies, their applicability in terms of
duration is limited with the acute stage [1]. Thrombolytic
tissue plasminogen activator (tPA) treatment could be
administered within 4.5 h from stroke onset [2]. In addition,
endovascular thrombectomy procedure, an innovative
strategy for mechanical removal of the clot, is performed

for patients not eligible for tPA administration [3]. The need
for prompt action in stroke patients is necessary to provide
regular circulation in the brain and to reduce the ischemiadependent injury. Even the patients are lucky enough to
retrieve the brain functions, long-lasting neurological effects
may be obtained [4]. These limitations make the development
of effective neuroprotective and neurorestorative substances
favored. To further broaden the restrictions of this area,
pharmacological, biotechnological, and electrophysiological
therapies that enhance neuroplasticity are being investigated
with a great interest [5].
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Neurotrophic factors are one of the specific biomolecules
that support neuroplasticity and neurogenesis. Hereby, as
they hold great potential for repair of neurodegeneration,
characteristics of neurotrophic factors were examined
in many aspects [6]. Glial cell-line derived neurotrophic
factor (GDNF) is one of the most well studied neurotrophic
factor due to its role on dopaminergic neurons by inducing
dopamine (DA) release in the striatum and promoting
morphological differentiation of striatal neurons [7–
9]. The accumulating evidence suggests that GDNF
can regulate striatal neurons’ survival, migration, and
differentiation [10]. Previous studies have demonstrated
that there is a close interaction or crosstalk between GDNF
and nuclear receptor related 1 (Nurr1), an essential orphan
ligand-activated transcription factor directly related with
dopaminergic functions. Nurr1 is highly expressed in the
developing and ventral midbrain and regulates the DA
metabolism and transportation. It was speculated that
blockade of GDNF in nigral DA neurons decreased the
Nurr1 and downstream target GDNF receptor tyrosine
kinase (RET) expression [11, 12].
Dopaminergic neurons are the primary source of DA
involved in motor and reward-related brain functions
[13]. In addition to the midbrain tegmentum, there is a
small portion of dopaminergic neurons located in the
striatum. Striatal dopaminergic neurons are unique
subtypes of gamma-aminobutyric acid (GABA)-ergic
interneurons, which are able to produce both DA and
GABA neurotransmitters [14]. Even though the exact
role of striatal dopaminergic neurons is still a mystery,
these locally acting neuronal subgroups are known to
be increased in number in animal models of Parkinson’s
disease (PD) [15]. DA also plays an essential role in other
neurodegenerative disorders like Huntington disease
(HD) and multiple sclerosis (MS) [16]. Recent clinical and
experimental findings demonstrated that alterations in
DA balance play a pivotal role in the motor and cognitive
symptoms of HD and decreased behavioral flexibility [17].
In addition, it is speculated that dopaminergic signaling
pathway regulates both de-myelination and re-myelination
in MS [18]. Considering this response by dopaminergic
striatal neurons, there must be a compensatory mechanism
carried out for dealing with the neuronal degeneration
[19].
Post-ischemic
stages
accompany
enormous
physiological events; transient occlusion of blood flow
gives rise to sudden cell death and initiates several
molecular processes in the primarily affected core
region [20]. We previously demonstrated the potential
role of lentiviral GDNF (Lv-GDNF) delivery on long
term neurological recovery [10]. Herein, our scope was
investigating the possible impact of GDNF treatment on
striatal dopaminergic neurons in the acute phase of stroke.

In this context, we hypothesized that GDNF could be used
as a neuroprotective agent for maintaining dopaminergic
neurons’ functions and, in the meanwhile, we aimed to
uncover the mechanisms behind GDNF’s action.
2. Materials and methods
2.1. Ethics statement
Experiments were performed in accordance to National
Institutes of Health (NIH) guidelines for the care and use
of laboratory animals and approved by local government
authorities (İstanbul Medipol University, Animal Research
Ethics Committee). All animals were held in a daily
lighting period of 12 h of light and 12 h of darkness.
Investigators were blinded for experimental groups at all
stages of experiments and data analysis.
2.2. Experimental groups
Experiments were performed using 14 male C57BL/6J
mice (8–10 weeks, 20–25 g). Adult mice were randomly
divided into two groups and administered with intrastriatal
delivery of vehicle (Lv-GFP) or lentiviral vector expressing
GDNF (Lv-GDNF). Ten days after intrastriatal injection,
mice were subjected to 30 min of middle cerebral artery
occlusion induced focal cerebral ischemia followed by 72 h
reperfusion. Seventy-two hours after ischemia, mice were
deeply anesthetized, decapitated, and brains were frozen
with dry ice. Following, brains were sectioned into 18 μm
coronal portions using a cryostat (CM1850-UV; Leica,
Germany).
2.3. Lentivirus production
A second-generation lentivirus packaging system was
used to produce vectors according to safety protocols.
After total RNA extraction from SH-SY5Y cell cultures
(80004, Qiagen, Germany), complementary DNA (cDNA)
was reversed from RNA templates (04896866001, Roche).
Human GDNF transcript variant 1 (NCBI Reference
Sequence: NM_000514.3) was amplified using the defined
primers (Forward: 5’- AGT CAG GTA CCA TGA AGT
TAT GGG ATG TCG TGG -3’ and reverse 5’- AGT CAG
CGG CCG CGG AGT CAG ATA CAT CCA CAC C -3’).
Both PCR products and lentiviral expression plasmid
pLenti (LV590 Applied Biological Materials, Canada) were
fast digested with restriction enzymes KpnI (FD0524,
Thermo Fisher Scientific, USA) and NotI (FD0593,
Thermo Fisher Scientific, USA). Next, ligation reaction
was performed with T4 DNA ligase (EL0014, Thermo
Fisher Scientific, USA) for obtaining an expression plasmid
with GDNF insert. pMD2.G and psPAX packaging
plasmids were kindly provided by Dr. Didier Trono
(Ecole Polytechnique Federale De Lausanne, France).
The plasmids were used as complementary vectors for
packaging the lenti-viral system. HEK293T cells (6 x106
cells) were seeded on 10 cm plates. Transfection process
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was carried out using Lipofectamine 3000 (L3000015,
Thermo Fisher Scientific, USA) for generating DNA-lipid
complex. pLenti (7 μg), pMD2.G (3.5 μg), and psPAX (7
μg) vectors mixed in lipid complex was applied to cells
drop by drop. The medium was supplemented with fresh
DMEM 6 h after transfection, and the cells were incubated
at 37 °C in a moist environment containing 5% CO2. The
whole medium was harvested twenty-four and fifty-two
hours after transfection, centrifuged for ten minutes at
2000 rpm, and screened with a low binding filter with a
pore size of 0.45 µm. Virus particles were collected after
ultracentrifugation at 100,000 g for 2 h and dissolved in
Dulbecco’s Phosphate-Buffered Saline (DPBS; P04-3650,
Pan Biotech, Germany) without calcium and magnesium.
As a control, an expression plasmid without any insert
DNA was packed using the same protocol as the GDNFcontaining one.
2.4. Calculation of virus titer
HEK293T cells were exposed to ten-fold serially diluted
virus particles ranging from 10–1 to 10–4, and the medium
was replaced every day for three days. Cells were treated
with trypsin, inactivated with culture media, spun, and
resuspended in cold phosphate buffer saline (PBS) for
fluorescence activated cell sorting (FACS) study after
adequate GFP signaling (Becton Dickson Influx cell
sorter, USA). Wells containing cells expressing between
1%–20% GFP were used to evaluate the titer of the virus
particles. According to the formula “Virus titer (TU/
ml=FxCn/(V(ml)) x Df “ multiplicity of infection (MOI)
was calculated as 108. F represents the frequency of GFPexpressing cells, Cn represents the total number of cells
infected (4x105), V represents the volume of the inoculum
(1 mL), and Df represents the virus dilution factor in this
calculation. According to titer measurements, viral vectors
were used at a concentration of 108 particles in 2 μL PBS
[21].
2.5. Virus injection
Mice were anesthetized with 1% isoflurane and placed
on a stereotactic frame (Stoelting, Illinois, USA). After
drilling the skull according to the unilateral coordinate
corresponding to the striatum (AP: bregma stage, ML: -2.5
mm, DV: +3 mm) Lv-GDNF or Lv-GFP viral particles were
administered into the left hemisphere via micro-syringe
pump controllers (Micro 4; World Precision Instrument,
USA).
2.6. Induction of cerebral ischemia
Mice were anesthetized with isoflurane (1%) and 30%
O2, reminder N2O. A feedback-controlled heating system
was used to maintain the necessary rectal temperature
of 36.5–37.0 °C (MAY instruments, Ankara, Turkey).
Laser Doppler Flowmetry measured cerebral blood flow
(CBF) during MCAO and reperfusion (LDF). To do so,
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tissue adhesive was used to bind a flexible 0.5 mm fiber
optic probe (Perimed, Sweden) to the intact skull above
the MCA territory (AP: +2 mm and ML: +6 mm from the
bregma). An intraluminal filament technique was used to
establish focal cerebral ischemia [22, 23]. The left common
and external carotid arteries were separated and ligated
after a small midline neck incision. Microvascular clips
were used to temporarily ligate the internal carotid artery
(FE691; Aesculap, Germany). For MCAO, a 180–190 µm
silicon coated (Xantropen; Bayer Dental, Japan) 8.0 nylon
monofilament (Ethilon; Ethicon, Germany) was implanted
into the normal carotid artery via a small incision
and advanced 9 mm distal to the carotid bifurcation.
Reperfusion was started 30 min later when the filament
was removed. LDF recordings were continued for 20 min
to check reperfusion. Wounds were gently sutured after
surgery, anesthesia was ended, and mice were returned to
their cages.
2.7. Immunofluorescence
For immunofluorescence analysis of tyrosine hydroxylase
(TH), sections from the bregma level were fixed in 4%
paraformaldehyde (PFA), rinsed, and submerged in 0.1 M
phosphate-buffered saline (PBS) containing 0.3%
Triton X-100 (PBS-T) and 10% normal goat serum (NGS)
for 1 h before being pretreated with citrate buffer for antigen
retrieval. The sections were then incubated overnight
at 4 °C with antibodies against TH (AB152, Millipore,
USA). The next day brain sections were incubated with
an Alexa Fluor 488 conjugated goat anti-rabbit secondary
antibody (A11034, Thermo Fisher Scientific, USA) at
room temperature. Then, sections were examined under
confocal microscopy (LSM 780, Carl Zeiss, Germany)
after counterstaining with 4′,6-diamidino-2-phenylindole
(DAPI; D9542, Sigma Aldrich, USA)) for detecting the
nuclei. Positively stained cells from 9 distinct regions of
interest (ROI), each having 62,500 μm2 area, were analyzed
from the ischemic striatum. For validating GNDF
expression, sections from the bregma level were stained
with anti-GDNF primary antibody (sc-13147, Santa Cruz
Biotechnology, USA) and Alexa Fluor 488 conjugated goat
anti-mouse secondary antibody (A11001, Thermo Fisher
Scientific) by following the same protocol.
2.8. Fluoro Jade C staining
To analyze neuronal degeneration after focal cerebral
ischemia, Fluoro Jade C staining was performed. Coronal
sections were fixed in PFA and washed with 0.1 M PBS
and dH2O successively. Next, the sections were incubated
in 80% ethanol with 1% NaOH for 5 min. After rinsing in
70% ethanol for 2 min, the sections were washed in dH2O
and incubated in 0.06% KMnO4 solution for 20 min. Then,
the slides were rewashed in dH2O and treated with Fluoro
Jade C working solution (A6325, Millipore) for 10 min in
the dark. After several washing steps, the brain sections
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were counterstained with DAPI for nuclear signal. Finally,
they were air dried, immersed with xylene, and mounted
with entellan (1079600500, Sigma Aldrich). Degenerated
neurons were monitorized and evaluated with confocal
microscopy (LSM 780, Carl Zeiss). Cells from 9 distinct
ROI, each having 62,500 μm2 area, were analyzed from the
ischemic striatum.
2.9. Western blot analysis
Ischemic and non-ischemic striatal regions were isolated
from the brain tissue samples. Radioimmunoprecipitation
assay (RIPA) lysis buffer (89900, Thermo Fisher Scientific)
containing a protease and phosphatase inhibitor mixture
(5872, Cell Signaling Technology, USA) was used to
homogenize samples from the same groups. After 15 min
of centrifugation at 14,000 rpm, proteins were removed.
BCA protein assay kit (23227; Thermo Fisher Scientific)
was used to determine protein concentrations. Just after
concentration determination, an equivalent volume of
protein samples (20 μg) was loaded into 4%–20% TGX
(Tris-glycine) gels (4561094, Biorad Life Sciences, USA)
run for 1 h at 150 V and then transferred to PVDF
membranes (162-0174, Biorad Life Sciences, USA).
Membranes were blocked for 1 h at room temperature
with 5% non-fat dry milk dissolved in Tris-buffered saline
containing Tween-20 (TBS-T). Antibodies against GDNF
(sc-13147, Santa Cruz Biotechnology), Nurr1 (sc376984,
Santa Cruz Biotechnology), Gap43 (5307, Cell Signaling),
iNOS (sc-650, Santa Cruz Biotechnology), nNOS (ab76067,
Abcam, United Kingdom), NF-κB (ab16502, Abcam) and
tyrosine hydroxylase (AB152, Millipore) were diluted in
%5 non-fat dry milk (sc-2324, Santa Cruz Biotechnology)
with TBS-T and incubated overnight on membranes. Next
day after several washing with TBS-T membranes were
incubated with the suitable secondary antibodies goat

anti-rabbit-HRP (7074, Cell Signaling Technology) or
goat anti-mouse-HRP (7076, Cell Signaling Technology)
for 1 h at room temperature. Then, TBS-T washed blots
were improved with a chemiluminescent substrate (ECL)
(K-12043-D10; Western Bright Sirius, Advansta, USA)
and visualized using a CCD camera cabinet (Fusion FX7,
Vilber, Germany). Membranes were stripped and reprobed with an anti-actin (4970, Cell Signaling) antibody
for protein normalization. Image J program (National
Institute of Health, USA) was used to measure the
densitometrical levels of proteins.
2.10. Statistical analysis
A software package was used to analyze statistical results
(SPSS for Windows; SPSS Inc., Chicago, IL, USA). The
independent-sample t test was used to determine the
variations between the classes, followed by least significant
differences (LSD) test. All values were expressed as mean
± standard deviation. The p values of less than 0.05 were
considered significant.
3. Results
3.1. GDNF overexpression was validated by Western blot
and immunofluorescence
Striatal tissue samples from the injection area were used
to confirm exacerbation in the amount of GDNF protein
expression. Results demonstrated that GDNF protein
content was significantly upregulated upon lentivirus
treatment (p = 0.004) (Figure 1A). In addition to this,
immunofluorescence staining of GDNF supported this
finding (Figure 1B).
3.2. Neither TH positively stained neurons nor TH
expression in the ischemic striatum was different from
control animals
Results showed that the number of TH positive neurons
reduced due to ischemic injury (Figure 2A). However,

1
Figure 1. Validation of GDNF overexpression. GDNF overexpression was confirmed via (A) Western blot and (B) immunofluorescence
staining from the striatum level. A representative image of Western blot analysis from three independent experiments was given above
their corresponding graph. Data are represented as mean ± standard deviation values of three independent experiments. **p < 0.01
compared to vehicle treated group. The scale bar represents 40 μm.
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there was no significant difference between the vehicle
or GDNF treated groups for the numbers of striatal
dopaminergic neurons both in the ipsilesional (p =
0.593) and contralesional hemispheres (p = 0.425).
Also, TH protein expression analysis indicated that TH
protein expressions were similar between the vehicle and
GDNF treated animals for both sides independent of the
treatment (Figure 2B).
3.3. GDNF overexpression in the ischemic striatum
reduced neuronal degeneration
The number of degenerated neurons after focal cerebral
ischemia was analyzed using Fluoro Jade C staining, which
is generally used to detect degenerated neurons (Figure
3). Results demonstrated that the number of degenerated
neurons in the ischemic striatum was significantly reduced
in the GDNF treated group (p = 0.045).
3.4. GDNF delivery regulated the production of the
orphan nuclear receptor Nurr1 and axonal membrane
protein GAP43
Western blot analysis demonstrated that lentiviral
GDNF administration significantly increased the orphan
transcription factor nuclear receptor-related 1 protein
(Nurr1) expression in the ischemic striatum (p ≤ 0.001)
(Figure 4A). However, Nurr1 protein expression was

1

significantly reduced in the contralesional striatum (p =
0.001). On the other hand, GDNF treatment slightly but
not significantly (p = 0.056) increased growth associated
protein 43’s (GAP43) protein expression, which plays
essential role after neuronal injury in the ipsilesional
striatum (Figure 4B). Notably, GAP43 was upregulated
in the Lv-GDNF applied animals in the contralesional
striatum (p = 0.041).
3.5. GDNF overexpression regulated proteins related to
inflammatory response and synaptic function
Expression of nuclear factor kappa B (NF-κB), a wellknown regulatory transcription factor of inflammatory
processes, and major enzymes responsible for the
production of vasodilator nitric oxide (NO), inducible
nitric oxide synthase (iNOS), and neuronal nitric
oxide synthase (nNOS) were analyzed by Western blot.
The data indicated that NF-κB protein expressions
increased significantly (p = 0.001) with Lv-GDNF in the
contralesional hemisphere (Figure 4C). At the same time,
there was only a moderate rise (p = 0.083) for inducible
nitric oxide synthase (iNOS) (Figure 4D). Like NF-κB,
nNOS protein expression increased significantly (p ≤
0.005) with Lv-GDNF in the contralesional hemisphere
(Figure 4E).

Figure 2. Analysis of striatal dopaminergic neurons. (A) The number of TH positive neurons was assessed from the immunofluorescence
staining from the striatum. In addition, (B) TH protein expression was analyzed from both ipsilesional and contralesional striatum. A
representative image of Western blot analysis from three independent experiments was given above their corresponding graphs. Data
are represented as mean ± standard deviation values of three independent experiments. The scale bar represents 40 μm.
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1

Figure 3. Analysis of degenerating neurons by Fluoro Jade C staining from the striatum level. Data are represented as mean ± standard
deviation values of three independent experiments. *p < 0.05 compared to vehicle treated group. The scale bar represents 40 μm.

4. Discussion
This study addressed the fundamental question of the
possible role of lentivirally induced GDNF expression
on dopaminergic neurons in the case of acute neuronal
degeneration. For this purpose, we designed an
experimental procedure firstly by focusing on the survival
of tyrosine hydroxylase (TH) positive dopaminergic
neurons.
Previous studies demonstrated that GDNF improves
behavioral functions, promotes neurogenesis, reduces
infarct size, increases synaptic plasticity, and decreases
apoptosis when applied as a recombinant protein, a TATfusion protein or via a viral vector in the post-acute phases
of stroke [10, 21, 24]. In this way, GDNF provides longterm neurological recovery by remodeling the brain.
Considering the limited time window for therapeutic
applications in clinics, the acute phase of stroke becomes
more of an issue. Therefore, we chose 30 min of intraluminal
MCAO followed by 72 h reperfusion model, which is the
more appropriate model to evaluate disseminated neuronal
injury in the acute phase of stroke [23]. While beneficial
effects of GDNF on neuronal functions have been reported
in most previous studies, our data will contribute to the
literature with the perspective of dopaminergic functions.
Since the accumulating evidence also suggests that GDNF
signaling in the striatum is essential for neuromodulation
of dopaminergic neurons, it requires constant stimulation
[9].
TH is a -limiting enzyme taking place during
the conversion of tyrosine to DOPA and is generally
considered a dopaminergic neuron marker [25].
Usually, dopaminergic neurons have a crucial role in
controlling numerous brain activities such as motor and
cognitive functions, including coordination of voluntary
movements, mood, reward, and stress-related responses
[26]. It is known by the past works that striatum harbors
a small number of dopaminergic neurons whose number
increase with pathological conditions [15]. At this point,

striatal dopaminergic neurons may be a great of interest in
neurodegeneration to develop novel therapeutic strategies.
After verifying the significant upregulation in GDNF
levels, TH expressing neurons were evaluated for finding
the possible impact of GDNF. It is evident that, Lv-GDNF
delivery didn’t have a profound action on dopaminergic
neuron survival as expected. This may be due to the
severity of the pathophysiological events in the acute stroke
such as intense necrosis, inflammation energy failure
and excitotoxicity [27]. This catastrophic environment
doesn’t exactly provide representation of recovery related
processes. For this reason, overall consequences of GDNF
therapy on dopamine system can be investigated in long
term. As noted earlier, it is well-known with numerous
experiments that GDNF has such a power to induce
neuroprotection on dopaminergic neurons under different
pathological conditions [28].
Fluoro Jade C is an efficient fluorescent dye used
as a degenerating neuron marker by many researchers.
Positive labeling by Fluoro Jade C indicates the existence
of degenerating neurons independent of the way of cell
death mechanism. Necrotic, apoptotic, and autophagic
cells can be detected in this manner easily [29]. Glutamate
excitotoxicity related neurotoxicity, a hallmark of ischemic
stroke pathophysiology can also be screened through
Fluoro Jade staining [30]. According to our analysis,
Lv-GDNF delivery protected neuronal degeneration.
Although GDNF has no apparent effect on dopaminergic
neurons, it can modulate dopaminergic neurons in the
aspect of neuronal death rather survival.
For further analyzing the molecular basis of
dopaminergic regulation Nurr1, a significant nuclear
receptor directly related with dopaminergic functions
was evaluated. Besides being an extraneous marker for
dopaminergic neurons, Nurr1 also targets some regulatory
elements, which designates GDNF signaling [11]. In this
way, Nurr1 and GDNF have a reciprocal interaction.
Nurr1 expression was demonstrated to be associated with
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Figure 4. Western blot analysis of (A) Nurr1, (B) GAP43, (C) iNOS, (D) iNOS, and (E) nNOS proteins. Representative images of
Western blot analysis from three independent experiments were given above their corresponding graph. Data are represented as mean
± standard deviation values of three independent experiments. ***p ≤ 0.001/ **p <0.01/ *p < 0.01 compared to vehicle treated group.

dopamine (DA) neurotransmission, and, by doing so, it
increases TH expression in dopaminergic neurons [31].
In this perspective, the dramatic rise in the expression
of Nurr1 in the ipsilateral striatum could be a straight
consequence of GDNF stimulation. According to our data,
contralesional striatum displayed an opposite outcome in
terms of Nurr1 expression.
An ischemic pathology induces impairments in
both hemispheres accordingly, neuronal remodeling is
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presumable as a bilateral activation during recovery [32].
It was an outstanding finding to show the relationship
between functional recovery and contralesional plasticity
through the reorganization of growth-associated
proteins [10]. In this context, distinct patterns of Nurr1
expression in either sides may be due to establishing
the interhemispheric balance. Despite having a similar
trend of increment upon Lv-GDNF treatment, growth
cone protein GAP43 was significantly higher only in the
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contralateral hemisphere. Previously, it was demonstrated
that insufficient neurite regeneration associated loss of
dopaminergic neurons correlates with reduced striatal
expression of GAP43 [33].
Lastly, within the scope of this study, inflammationrelated proteins were examined. There was a similar pattern
of expression for proteins NF-κB, iNOS, and nNOS whose
amounts increased in the contralateral hemisphere. This
may be due to decreased levels of Nurr1, since it is known
that Nurr1 is a potent antiinflammatory factor, which can
modulate inflammatory responses [34]. NF-κB is a versatile
transcription factor involved in multiple cellular functions
in the nervous system. Due to its master regulatory role
for inflammation, it is also quite critical for the regulation
of apoptosis [35]. Here, when NF-κB is considered as a
junction between inflammation and apoptosis pathways,
there may be possible crosstalk between them. One of
the downstream pro-inflammatory mediators of NF-κB
is iNOS whose activation is expected to contribute to
ischemic damage [35]. According to the basic knowledge
about inflammatory processes, nNOS and iNOS are direct
supporters of tissue destruction through high-output NO
(nitric oxide) synthesis. However, recent data reveals their
protective role by virtue of regulatory functions [36, 37].
Even though nNOS and iNOS seem to play a destructive
role, one such protective mechanism can be maintained
over NO production, which contributes to post-ischemic
recovery by stimulating vasodilation and increasing blood
flow [38]. These results elucidate that those inflammatory
mechanisms can be regulated in a complicated manner,

and GDNF has a part in this organization by dynamically
modulating contralesional molecular processes.
5. Conclusion
In recent years, neurotrophic factors such as nerve growth
factor, brain-derived neurotrophic factor, and neurotrophin
have been used to treat neurodegenerative diseases,
including cerebral ischemia. The approach presented here
was constructed on the behavior of striatal dopaminergic
neurons after GDNF treatment for ischemic damage. The
accumulating evidence indicated the potential curative
role of GDNF on dopaminergic neurons. Even though
our previous study showed the increased neuroplasticity,
neurogenesis, and neuronal re-modeling upon Lv-GDNF
delivery, the current study showed the relationship between
GDNF and survival of the striatal dopaminergic neurons.
However, this study highlighted the importance of Nurr1
as a major regulatory element and its possible interaction
with GDNF. It is interesting to note that finding novel
therapeutic strategies for ischemic stroke will be available
only with better understanding and explaining the
ischemic pathology with different aspects. In this context,
GDNF and dopaminergic neurons perfectly match puzzle
pieces to enlighten ischemia pathophysiology and open
ways for regenerative treatments.
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